Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study

Table 2

Changes of various parameters between baseline and 3 months later.

Parameters	Teneligliptin continued group	Canagliflozin add-on group
ΔBody weight (kg)			<0.0001
ΔBMI (kg/m^2)		-0.9 ± 0.7	<0.0001
ΔFPG (mg/dL)			0.0003
ΔHbA1c (%)			<0.0001
ΔSystolic BP (mmHg)			n.s.
ΔDiastolic BP (mmHg)			n.s.
ΔAST (U/L)			n.s.
ΔALT (U/L)			n.s.
ΔγGTP (U/L)			0.03
ΔCre (mg/dL)			0.01
ΔBUN (mg/dL)			0.001
ΔeGFR (mL/min/1.73 m^2)			0.04
ΔTriglyceride (mg/dL)			n.s.
ΔHDL cholesterol (mg/dL)			n.s.
ΔLDL cholesterol (mg/dL)			n.s.
ΔUric acid (mg/dL)			0.02